Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson's Disease

Area of Science:

• Neuroscience
• Immunology
• Pathology

Background:

• Microglial activation and pro-inflammatory cytokine release are implicated in Parkinson's disease (PD) pathogenesis.
• Chronic neuroinflammation mechanisms in PD remain incompletely understood.
• Elevated NLRP3 inflammasome levels are observed in activated microglia within the substantia nigra of PD patients.

Purpose of the Study:

• To review the role of the alpha-synuclein (α-syn)/toll-like receptors (TLRs)/nuclear factor kappa-B (NF-κB)/NLRP3 inflammasome axis and microglial activation in PD.
• To summarize recent advancements in targeting this axis for PD treatment.

Main Methods:

• Review of emerging studies on neuroinflammation in Parkinson's disease.
• Analysis of the molecular mechanisms linking α-syn aggregation to microglial activation and neuroinflammation.
• Synthesis of current research on therapeutic strategies targeting the α-syn/TLRs/NF-κB/NLRP3 inflammasome axis.

Main Results:

• Abnormal α-syn aggregation activates microglial NLRP3 inflammasome via TLRs.
• This activation leads to NF-κB translocation, pro-inflammatory cytokine release, mitochondrial dysfunction, and dopaminergic neuron damage.
• The α-syn/TLRs/NF-κB/NLRP3 inflammasome axis is a key driver of PD pathology.

Conclusions:

• The α-syn/TLRs/NF-κB/NLRP3 inflammasome axis in microglia is a critical component of PD pathogenesis.
• Inhibiting microglial activation via this pathway presents a potential therapeutic target for halting or reversing PD progression.
• Current PD treatments primarily manage symptoms, highlighting the need for disease-modifying strategies.